Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | CHKA | P35790 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL803112 | 0.89 | PTGS2 (0.41) | PTGS2PTGS1 | |
| SCHEMBL17616206 | 0.88 | RARB (0.38) | CHKAPTGS2PTGS1 | |
| SCHEMBL803431 | 0.87 | PTGS2 (0.40) | PTGS2PTGS1 | |
| SCHEMBL4549715 | 0.87 | PTGS2 (0.40) | PTGS2PTGS1 | |
| SCHEMBL17548830 | 0.87 | PTGS2 (0.40) | PTGS2PTGS1 | |
| SCHEMBL19798106 | 0.86 | BACE1 (0.38) | CYP1A2CYP2A6TAAR1FFAR4BACE1 | |
| SCHEMBL19196919 | 0.86 | CYP2A6 (0.37) | CYP1A2CYP2A6FFAR4BACE1FFAR1 | |
| SCHEMBL19197803 | 0.86 | ESR1 (0.36) | CYP1A2CYP2A6TAAR1FFAR4BACE1 | |
| SCHEMBL12172447 | 0.86 | RARB (0.38) | — | |
| SCHEMBL14211939 | 0.85 | PTGS2 (0.39) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230323209-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2023-10-12 | — | — | US | disclosed |
| US-20230287272-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DEVICE | DIC CORPORATION (JP) | 2023-09-14 | — | — | US | disclosed |
| US-20230272282-A1 | LC MIXTURES WITH NEGATIVE DELTA EPSILONCONTAINING CC-4-V1 AND COB(S)-N-OM | MERCK PATENT GMBH (DE) | 2023-08-31 | — | — | US | disclosed |
| US-11739270-B2 | Polymerizable compound as well as liquid crystal composition and liquid crystal display device each including polymerizable compound | DIC CORPORATION (JP) | 2023-08-29 | — | — | US | disclosed |
| US-11639327-B2 | Polymerizable compound, and liquid crystal composition and liquid crystal display device using the same | DIC CORPORATION (JP) | 2023-05-02 | — | — | US | disclosed |
| US-20180208846-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE INCLUDING THE SAME | DIC CORPORATION (JP) | 2018-07-26 | — | — | US | disclosed |
| US-20180187079-A1 | COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE USING THE SAME | DIC CORPORATION (JP) | 2018-07-05 | — | — | US | disclosed |
| US-20180030346-A1 | NEMATIC LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT MANUFACTURED USING SAME | DIC CORPORATION (JP) | 2018-02-01 | — | — | US | disclosed |
| US-20170253800-A1 | NEMATIC LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE USING THE SAME | DIC CORPORATION (JP) | 2017-09-07 | — | — | US | disclosed |
| US-20170218270-A1 | LIQUID-CRYSTAL DISPLAY | DIC CORPORATION (JP) | 2017-08-03 | — | — | US | disclosed |
| US-20170218271-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE USING THE SAME | DIC CORPORATION (JP) | 2017-08-03 | — | — | US | disclosed |
| US-20170210988-A1 | LIQUID-CRYSTAL DISPLAY ELEMENT | DIC CORPORATION (JP) | 2017-07-27 | — | — | US | disclosed |
| US-20170045765-A1 | LCD DEVICE | DIC CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739270-B2 | Polymerizable compound as well as liquid crystal composition and liquid crystal display device each including polymerizable compound | OCIAD2, PKN2, SKP1 | CYP1A2 2601/4885CYP2A6 1463/4885TAAR1 2597/4885 |
| US-20180030346-A1 | NEMATIC LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT MANUFACTURED USING SAME | LBR, VSIR, KIF23 | CYP1A2 4385/4885CYP2A6 4747/4885TAAR1 1295/4885 |
| US-11639327-B2 | Polymerizable compound, and liquid crystal composition and liquid crystal display device using the same | SKP1, PKN1, KTN1 | CYP1A2 3295/4885CYP2A6 4156/4885TAAR1 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.